Stable, tested and effective staphylococcal vaccines

ABOUT US



ImmLab was founded  in 1998 and is based in Birmingham, AL, USA. ImmLab performs continuous research in Immunology, Microbiology and Proteomics of present and future products at our subsidiary in Europe.

Our mission


Our mission is to significantly improve the prevention and treatment of microbial infections. In particular, we are focused on increasing the treatment options for people infected with the Staphylococcus aureus(S. aureus). The technology we have developed has particular application for the treatment and prevention of infections by antibiotic resistant strains of S. aureus. A key target population for our technology is the group of individuals at increased risk of exposure to and infection by S. aureus strains, especially antibiotic resistant strains such as methicillin-resistant strains (MRSA), vancomycin-intermediate strains (VISA) and vancomycin-resistant strains (VRSA). ImmLab technology would have a role for pre-treatment of those facing elective surgery or any other non-urgent invasive treatment.  

In addition to use in human populations, ImmLab’s products have important application in the dairy industry by providing a non-antibiotic option for preventing staphylococcal infection of the udder (mastitis) in calves, before the calves reach a productive age. Additional non-human uses include the use of ImmLab’s products for treatment of S. aureus skin infections in small animals, including companions and fur bearing animals. 

We are dedicated to using our technology platform to extend the applications and products to treatment and prevention of infections such as a new emerging staphylococcal strain ST398 and other bacterial strains according to actual epidemiological situation.  The technology and product line being developed by ImmLab will not only improve the health and well-being of people and animals subject to microbial infection, but will do so using an approach that will not add to the growing threat of antibiotic resistant bacterial strains. 

Immlab’s technologies make it possible to manufacture novel preparations that contain biologically active components derived from S. aureus. The biologically active components in ImmLab's therapeutic preparations activate both innate and acquired immunity, including humoral and cell-mediated responses. Treatments with ImmLab’s preparations are efficient, cost-effective and may easily be carried out with nasal drops or injections for human use, as well as injections for animal use. Therefore, ImmLab’s commitment is to improve the diagnostics, treatment and prevention of bacterial infections.  ImmLab will provide innovative, practical and top-quality products that will improve the health of humans and animals suffering from life threatening infections due to existing and emerging antibiotic-resistant bacterial strains.

Immunology Laboratories, Inc.